Počet záznamov: 1
myasthenia gravis, autoimunitná experimentálna
SYS d020720 LBL 00000cx--j2200000---45-- 005 20240119200324.7 100 $a 19991105asloy0103----ba0 152 $b mesh 250 $a myasthenia gravis, autoimunitná experimentálna $x BL $x CF $x CI $x CL $x CN $x CO $x DG $x DH $x DI $x DT $x EC $x EH $x EM $x EN $x EP $x ET $x GE $x HI $x IM $x ME $x MI $x MO $x NU $x PA $x PC $x PP $x PS $x PX $x RH $x RT $x SU $x TH $x UR $x VE $x VI $8 slo 300 1-
$a 2005 (2000) $8 eng 300 1-
$a Autoimmune Diseases (1969-1999) $8 eng 300 1-
$a Myasthenia Gravis (1968-1999) $8 eng 330 1-
$a Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3) $8 eng 450 $a Myasthenia Gravis, Experimental Autoimmune $5 e $8 eng 450 $a Passive Transfer Experimental Autoimmune Myasthenia Gravis $5 e $8 eng 450 $a myasténia gravis, autoimunitná experimentálna, pasívny prenos $5 e $8 slo 675 $a 616.831.8-009.17-021.6 686 $a C10.114.656.300 686 $a C10.114.703.350 686 $a C10.668.758.725.300 686 $a C20.111.258.500.300 686 $a C20.111.258.625.350 686 $a E05.598.500.500.750 750 $a Myasthenia Gravis, Autoimmune, Experimental $8 eng 801 -0
$a US $b DNLM $c 19991105 801 -2
$a SK $b BA006 $c 20050311 801 -2
$a SK $b BA006 $c 20201215 980 $x M
Počet záznamov: 1